More Publications by © Chronicle Companies

n+p.PNG
Advertise with Derm.city
Chronicle Companies
Terms of Use Policy
Order "To Heal the Skin"

© Chronicle Companies 2018

Powered by Skin Chronicle International

  • Twitter - Black Circle
  • Facebook - Black Circle
  • YouTube - Black Circle
  • Home

  • Skin Chronicle

  • Primers for your Patient

  • Skin Spectrum Summit

  • Chronicle

  • Contact

  • More...

    Genital psoriasis under-identified, has significant impact on patient QoL

    April 12, 2018

    |

    by John Evans

    Genital involvement in psoriasis is more common than many physicians believe, and it can have a profound impact on patient quality of life— even greater than with face and hand involvement, said Dr. Lyn Guenther, speaking at Dermatology Update in Vancouver in October.

     

    Results from various questionnaires suggest the prevalence of genital psoriasis ranges from 29% to 46%, said Dr. Guenther, professor of dermatology at western University in London, Ont., and past president of the canadian society for Dermatologic surgery. however, she said that if a practitioner asks a psoriasis patient if they have genital involvement, the patient will often say they do not, even if on visual examination they have “a napkin worth of psoriasis” in their genital area.

     

    Mistaken for VD, fungal infection

    “Many patients think they have a venereal disease,” she said. "I think this is part of the reason they do not want to bring it to [a physician’s] attention."

     

    Other health care practitioners who encounter the patient may misdiagnose genital psoriasis as a fungal infection and start the patient on anti-fungal therapy, Dr. Guenther said. That may be in part because of the atypical appearance of psoriasis in the genital area. “Often we do not see a large amount of scale because of the maceration of the area. But it is usually bright red.”

     

    Risk factors for genital involvement in psoriasis include inverse psoriasis—as many as 80% of psoriasis patients with inverse psoriasis will have genital involvement, Dr. Guenther said—and male gender, scalp involvement, and nail involvement are also risks. 

     

    QoL impact as severe as facial Pso 

    While dermatologists typically talk about psoriasis sited in visible areas, such as the hands and face, having the most impact on patient quality of life, Dr. Guenther said there are studies that show genital psoriasis can result in even more significant impairment of quality of life. 

     

    “[Genital psoriasis] has a large impact on sexual health,” she said. not only are the lesions aesthetically unappealing, “[the lesions] can also be associated with burning when [a patient] has intercourse, [as well as] redness and bleeding.” additionally, in one-third of patients, intercourse aggravates their psoriasis, and that aggravation is another factor that discourages sexual contact. 

     

    Treatment challenges

    There is little existing data on how to treat psoriasis in the genital area, noted Dr. Guenther. “There have been a few open-label trials of topical therapies. There have been some algorithms that have come up. There are some scattered case reports,” she said.

     

    “The skin is also very sensitive [in the genital area], more apt to have adverse effects,” she said.

     

    Tazarotene and ultraviolet (UV) light should be avoided in the genital area, partly due to the risk of irritation, and partly because the logistical challenges of exposing the area to the UV source, she said.

     

    The first-line therapy recommended by the few algorithms that have been developed is typically topical corticosteroids. “we will generally start with the weaker ones and then go to stronger ones for short periods of time,” she said. however, Dr. Guenther said in her own practice she has seen skin thinning and striae from topical steroids used in the genital area, which suggests use of stronger steroids should be minimized. 

     

    “Often the weaker steroids, though, just do not [resolve the psoriasis],” she said. Topical calcineurin inhibitors are her first-line therapies, particulary if there is a reason not to use steroids in a particular patient.

     

    She cited an open-label study (J Cutan Med Surg, sept./Oct. 2008; 12(5):230–234), in which 12 male patients with genital psoriasis were treated with topical tacrolimus 0.1% ointment twice daily for eight weeks, followed by four-weeks of observation.

     

    In that study the mean genital PASI scores decreased to 1.2 at week eight from 15.8 at baseline (p<0.001).

     

    If local treatments do not work, or the genital psoriasis is more severe or recalcitrant, treatment can be modified to include systemic agents, she said. 

     

    There has been a clinical trial of ixekizumab for genital psoriasis in which Dr. Guenther participated. The findings were presented at the sexual Medicine society of north america’s Fall 2017 scientific Meeting (abstracts 012, 203, and 204).

     

    Because the presentation of genital psoriasis frequently has less scaling, a new grading system was developed for evaluating genital involvement in this trial, Dr. Guenther said. approximately 40% of the 149 participants had less than 10% body surface area (Bsa) involvement, but all participants were graded as having moderate to severe psoriasis based in part on genital involvement. Genital areas evaluated included the labia minora, labia majora, and the perineum in female participants, and the penis, scrotum, and perineum in male participants.

     

    Improvements seen early

    Of the patients in the active 80 mg ixekizumab group, significant improvements vs. placebo were seen as early as week one, and by week 12, 73% of the active-arm patients had achieved clear or almost clear skin vs. 8% in the placebo arm.

     

    “At two weeks there was improvement in genital itching [in the active arm],” said Dr. Guenther. it was also noted that there was also significant improvment in sexual function, she added.

     

    Dr. Guenther said that she hoped dermatologists would not just ask patients if they have genital psoriasis, but check the area to be sure and if psoriasis is present, reassure them that it is common and offer them treatment, “Because [treatment] can have a major impact on their quality of life.”

     

    Non-proprietary and brand names of therapies: tazarotene (Tazorac, Allergan); tacrolimus 0.1% (Protopic, LEO Pharma); ixekizumab (Taltz, Lilly).
     

    Originally published in The Chronicle of Skin & Allergy (December 2017; 23(8):page 1,21) 

    Tags:

    Psoriasis

    genital psoriasis

    Treatment

    Ixekizumab

    Please reload

    Featured Posts

    High-dose brachytherapy for BCC, SCC in older patients

    December 6, 2019

    Study: Makeup Products May Harbor Dangerous Bacteria

    December 4, 2019

    Newborn's immune system detects harmful skin bacteria

    December 2, 2019

    Topical rapamycin may slow skin aging

    November 29, 2019

    Statin medications may leave patients vulnerable to skin infections

    November 27, 2019

    Genes show how much sun exposure could lead to melanoma

    November 25, 2019

    Atopic eczema increases fracture risk

    November 22, 2019

    Identifying hyperhotspots in genome could be key in preventative skin cancer treatment

    November 20, 2019

    New guidelines for opioid prescribing practices for dermatologists

    November 18, 2019

    More effective rituximab dosing for pemphigus identified

    November 15, 2019

    Please reload

    Archive

    December 2019 (3)

    November 2019 (11)

    October 2019 (11)

    September 2019 (13)

    August 2019 (13)

    July 2019 (12)

    June 2019 (11)

    May 2019 (17)

    April 2019 (15)

    March 2019 (13)

    February 2019 (11)

    January 2019 (13)

    December 2018 (12)

    November 2018 (13)

    October 2018 (14)

    September 2018 (9)

    August 2018 (9)

    July 2018 (9)

    June 2018 (13)

    May 2018 (11)

    April 2018 (13)

    March 2018 (13)

    February 2018 (14)

    January 2018 (12)

    December 2017 (6)

    November 2017 (11)

    October 2017 (5)

    September 2017 (4)

    August 2017 (6)

    July 2017 (10)

    June 2017 (12)

    May 2017 (17)

    April 2017 (12)

    March 2017 (19)

    February 2017 (11)

    January 2017 (13)

    December 2016 (11)

    November 2016 (13)

    October 2016 (16)

    September 2016 (16)

    August 2016 (14)

    July 2016 (16)

    June 2016 (16)

    May 2016 (22)

    April 2016 (17)

    March 2016 (15)

    February 2016 (12)

    January 2016 (11)

    December 2015 (13)

    November 2015 (19)

    October 2015 (13)

    September 2015 (15)

    July 2015 (3)

    June 2015 (22)

    March 2015 (3)

    Please reload

    Follow Us
    • Grey Facebook Icon
    • Grey YouTube Icon
    • Grey Instagram Icon
    • Grey Twitter Icon